BEIJING, August 8, 2025-- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), entered into a strategic collaboration agreement with MegaRobo Technologies. The two parties will advance the digital and intelligent upgrade of fully human antibody discovery and production by leveraging their complementary strengths, collaborating in key areas such as intelligent automation and R&D efficiency. Together, they will build a highly efficient, data-driven, and scalable R&D and manufacturing system that will drive the high-quality development of the biopharmaceutical industry.
Dr. Yuelei Shen, President and CEO of Biocytogen, said, “Digitalization and intelligent automation are shaping the future of drug development. Building on our RenMice® based ‘RenBiologics™’ program, we have created an industry-leading platform for large-scale, fully human antibody discovery. This collaboration will infuse advanced digital technologies and automation across the entire workflow, enabling a more efficient, intelligent, and scalable R&D and manufacturing system. We believe this partnership will not only accelerate the pace of antibody innovation, but also help establish new AI- and automation-driven models that support the sustainable growth of the biopharmaceutical industry.”
Dr. Yan Zhang, Co-founder and Senior Vice President of MegaRobo, commented: “Breakthroughs in life sciences are driven by the deep integration of cutting-edge technologies with real-world applications. This collaboration integrates MegaRobo’s versatile autonomous agents and AI-powered intelligent laboratory operating system with Biocytogen’s ‘RenBiologics™’ program and advanced RenMice™ platform, tackling core challenges in large-scale antibody discovery—from high-throughput sample processing to the integration of millions of data points—while establishing a replicable paradigm for technological advancement. By uniting our strengths, we aim to accelerate the digital and intelligent transformation of antibody R&D, set a benchmark for AI for Science in biopharmaceutical industrialization, and enhance the global competitiveness of China’s biopharmaceutical industry.”
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
ABOUT MEGAROBO
MegaRobo is a leading provider of autonomous agents in robotics applications in China, dedicated to providing a comprehensive suite of autonomous agents and multi-agent solutions for businesses across both laboratory and manufacturing settings. Through intelligent software-hardware ecosystems, we propel industries toward a future defined by efficiency, precision, and sustainability.
Underpinned by proprietary robotics automation and AI technologies across perception, conception and execution, our versatile autonomous agents excel at independently performing complex tasks while being easily configured and deployed at scale for different scenarios based on the modular design - liberating human talents to focus on high-impact workflows, empowering businesses to master intelligence-driven transformation, and future-proofed for the next era of research, manufacturing and beyond.
MegaRobo is committed to advancing the iteration of autonomous agents and deepening its industry expertise to transcend traditional boundaries in laboratory and manufacturing scenarios. By leveraging our technological leadership and product innovation, we serve the life sciences, fine chemicals, and precision agriculture, as well as consumer-grade integrated circuits and new energy sectors, while strategically expanding into emerging sectors.
We enable global partners to architect intelligent organizations, break through technological barriers, and redefine operational paradigms. As a catalyst of industrial evolution, we stand committed to being the premier collaborator in driving paradigm-shifting upgrades and sustainable value creation.
Biocytogen Contacts
Antibody assets and platforms: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
